BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 10, 2025
See today's BioWorld Asia
Home
» Aslan signs $138.5M licensing deal with Zenyaku for atopic dermatitis drug eblasakimab in Japan
To read the full story,
subscribe
or
sign in
.
Aslan signs $138.5M licensing deal with Zenyaku for atopic dermatitis drug eblasakimab in Japan
June 27, 2023
By
Marian (YoonJee) Chu
No Comments
Aslan Pharmaceuticals Pte Ltd. said it inked a licensing deal with Zenyaku Kogyo Co. Ltd. for its atopic dermatitis-targeting monoclonal antibody, eblasakimab, that could reach $138.5 million in up-front and milestone payments.
BioWorld Asia
Deals and M&A
Dermatologic
Japan
